BioXcel Therapeutics Inc at Bank of America Global Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : Great. That's a great intro. It is an exciting time. You have the 2 pivotal readouts coming. Maybe we could talk about the safety and efficacy bars for success in the SERENITY III trial data, which we should get this month. What should we be looking for here as important factors to consider? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MAY 09, 2023 / 5:15PM, BTAI.OQ - BioXcel Therapeutics Inc at Bank of America Global Healthcare Conference

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : Great. And how are you thinking about the bar for success there?

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : Okay, great. And then the other one that's a big focus among investors is TRANQUILITY II in Alzheimer's agitation. What should we be looking for in this update and in this setting?

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : Okay. And as far as efficacy, what is the bar there in your mind for a successful trial? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MAY 09, 2023 / 5:15PM, BTAI.OQ - BioXcel Therapeutics Inc at Bank of America Global Healthcare Conference

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : Great. And then there's also the Phase I healthy volunteer study in major depressive disorder that's coming soon. Maybe just how you're thinking about the importance of showing the daily chronic dosing.

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : Great. Matt, maybe a couple for you on the IGALMI launch. You noted that formulary wins have doubled. Maybe just an update there. And how does that turn into subsequent sales for the program down the road?

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : Got it. Okay. I guess how do we go about translating that into projecting revenues going forward? And when would you expect to see an inflection point in this initial setting?

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : Got it. Just a couple of minutes left, but I wanted to make sure and touch on OnkosXcel. Maybe Vimal, if you could walk us through a little bit the data at the recent updated ASCO GU and what we've seen there so far?

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : Okay. Great. There's about 30 seconds left, but just wanted to see about the next steps for 701 as far as additional tumor types and where you see the overall potential of the program.

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : Great. Well, with that, our time is up, but I'd like to thank you for joining us today. A great discussion, and thanks everyone out there for listening.